AUTHORS
Aditi Sharma, MD, Yingzhu Chen, MS2, Rasheda Browne, MD3, Marielle Jensen-Battaglia4, Soroush Mortaz-Hedjri, MD5, Emily Oh6, Michael Sohn, PhD7, Rachael Tylock8, Jason Mendler, MD, PhD9, Jane Liesveld, MD10, Rachel Rodenbach, MD, MS11, Eric Huselton, MD12, Craig Maguire13, Bassil Botros, MD14, Daniel R Richardson, MD,MSc,MA15, Heidi Klepin, MD16, Omer Jamy, MD17, Ilana Massi18, Kah Poh (Melissa) Loh, MD, MS19
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Rochester Medical Center, Rochester, New York, United States
3 University of Rochester Medical Center, Rochester, New York, United States
4 Yale University, New Haven, Connecticut, United States
5 University of Rochester Medical Center, Rochester, New York, United States
6 University of Rochester Medical Center, Rochester, New York, United States
7 University of Rochester Medical Center, Rochester, New York, United States
8 University of Rochester Medical Center, Rochester, New York, United States
9 University of Rochester Medical Center, Rochester, New York, United States
10 University of Rochester Medical Center, Rochester, New York, United States
11 University of Rochester Medical Center, Rochester, New York, United States
12 University of Rochester Medical Center, Rochester, New York, United States
13 University of Rochester Medical Center, Rochester, New York, United States
14 University of Rochester Medical Center, Rochester, New York, United States
15 University of North Carolina, Chapel Hill, North Carolina, United States
16 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
17 University of Alabama at Birmingham, Birmingham, Alabama, United States
18 Myeloid Cancer Advisory Board, University of Rochester Medical Center, Rochester, New York, United States
19 University of Rochester Medical Center, Rochester, New York, United States
ABSTRACT
Introduction
Older adults with acute myeloid leukemia (AML) have short survival, and many value time at home, yet this outcome remains understudied. Prior estimates by treatment intensity vary across measures and lengths of follow-up, and none has related time at home to geriatric assessment (GA)-defined fitness. We quantified days alive and out of hospital (DAOH) at fixed landmarks by treatment intensity and examined its association with baseline GA-defined fitness.
Methods
We performed a secondary analysis of UR-GOAL 2 (NCT05335369; PI: Loh), a pilot randomized trial of a communication tool in adults aged ≥60 years with newly diagnosed AML who completed a GA at diagnosis. Treatment was grouped as intensive, lower-intensity, or best supportive care (BSC). DAOH was calculated at 90, 180, and 365 days from diagnosis as days alive minus inpatient days abstracted from the electronic health record, with higher values indicating more days out of hospital. Patients who died contributed days only until death. Baseline GA impairment was counted across 5 domains (physical function, cognition, psychological health, nutrition, and polypharmacy), giving a deficit count of 0 to 5. Patients were grouped by this count into 3 fitness categories, fit (0), vulnerable (1-2), or frail (≥3). The primary comparison was intensive vs lower-intensity; BSC was reported descriptively. Groups were compared with Wilcoxon rank-sum, Kruskal-Wallis, and Fisher's exact tests, and unadjusted median differences with 95% confidence intervals (CI) were estimated by median (quantile) regression. The association of fitness with DAOH-180 was tested within each intensity group, both as fitness category and as a continuous deficit count. Overall survival was estimated by Kaplan-Meier and compared by log-rank test. Sensitivity analyses repeated DAOH-90 among 90-day survivors and excluding patients transplanted by day 90.
Results
Of 97 patients, 32 received intensive therapy, 55 lower-intensity (51 hypomethylating agent with venetoclax), and 10 BSC; DAOH-90 was evaluable in 90 (31, 52, and 7). Intensively treated patients were younger (median age 69 vs 77 years, p<0.001) and more often underwent transplant (50% vs 24%, p=0.02). Baseline AML risk, ECOG performance status, and GA fitness category did not differ between intensive and lower-intensity therapy (p=0.37, 0.92, and 0.63). Among 93 patients with complete GA, 15 were fit, 61 vulnerable, and 17 frail. Median DAOH-90 was 54 days (interquartile range [IQR] 45-76) with intensive therapy, 78 days (IQR 54-89.5) with lower-intensity therapy, and 15 days (IQR 0-66) with BSC; median inpatient days were 33, 9, and 5. Kaplan-Meier 90-day survival was 87.5%, 83.6%, and 20.0%. The median DAOH-90 difference (lower-intensity minus intensive) was 24 days (95% CI 9.8-30.3, p=0.012); inpatient days (33 vs 9, p=0.002) and hospitalizations (2 vs 1, p=0.02) also differed. Among 90-day survivors (n=27 and 43), the difference was 28 days (95% CI 18.3-30.9, p=0.001), and 24 days after excluding the 2 lower-intensity patients transplanted by day 90 (95% CI 9.9-30.3, p=0.010). Median differences were 17 days at 180 days (95% CI 7.8-31.7, p=0.046) and 29 days at 365 days (95% CI -2.0 to 41.1, p=0.19). Median overall survival was 476 vs 597 days, and survival did not differ over full follow-up (20 and 29 deaths, log-rank p=0.95). Baseline GA-defined fitness was not associated with DAOH-180 in the intensive (p=0.83) or lower-intensity group (p=0.75), and results were similar with the deficit count modeled continuously (-5.5 and -2.0 days per deficit, both 95% CI including 0).
Conclusion
In older adults with newly diagnosed AML, lower-intensity therapy was associated with 24 more days alive and out of hospital over the first 90 days than intensive therapy. The difference persisted among patients who survived to day 90, reflecting more time in hospital with intensive therapy. To our knowledge, this is the first study to quantify DAOH in a cohort with prospectively collected GA. Baseline GA-defined fitness was not associated with DAOH at 180 days in either treatment group. Quantifying time at home can inform treatment decisions. Because treatment was not randomized, patients receiving each therapy differed at baseline, and these findings warrant confirmation in larger multicenter studies.
DISCLOSURES
Aditi Sharma, MD: No relevant conflicts of interest to declare.